glp-1 drugs for parkinson's disease drug shows little benefit people with | UCL News GLP-1 receptor agonists show promise
Description
Molecular mechanisms of chromium in alleviating insulin resistance
Development of a first-in-class unimolecular dual GIP/GLP-2 analogue, GL-0001, for the treatment of bone fragility
Patients accessed Semaglutide and Tirzepatide at $150$300/month versus $1,000+ for branded products
Targeting enteral endocrinal L-cells with dietary carbohydrates, by increasing the availability of miglitol in the intestinal lumen, leads to multi-fold enhancement of plasma glucagon-like peptide-1 levels in non-diabetic canines
Purification and chemical characterization of a glicentin-related pancreatic peptide (proglucagon fragment) from porcine pancreas
